載入...
Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10
Treatment options for women with recurrent ovarian cancer who have received two or more prior lines of chemotherapy have recently expanded with the U.S. Food and Drug Administration (FDA) and European Commission (EC) approvals of the poly(ADP‐ribose) polymerase (PARP) inhibitor rucaparib. As more on...
Na minha lista:
| 發表在: | Oncologist |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley & Sons, Inc.
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6964123/ https://ncbi.nlm.nih.gov/pubmed/31575788 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0229 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|